Background: Neudesin is a peptide secreted in brain and adipose tissues that has neural and metabolic functions. Its role as regulator of energy expenditure leads to assumption that its level may be regulated depending on thyroid gland pathology. Objective: This study aimed to investigate serum neudesin levels in patients with thyroidism and to evaluate1 any possible relationship between plasma neudesin levels and thyroid hormone levels. Methods: The study included 100 women with newly diagnosed thyroidisim were subdivided into two groups: hyperthyroidism group (50 female patients with age ranged from 18 to 60 years) and hypothyroidism group (50 female patients with age ranged from 18 to 75 years). A control group (30 healthy females with age ranged from 18 to 70 years) was also included for comparison. Body mass index (BMI) was evaluated. Plasma glucose, lipid profile, triiodothyronine (T3), thyroxin (T4), free T3, free T4, thyroid stimulating hormone (TSH), and neudesin levels were evaluated in all participants using ELISA kit. Results: The hyperthyroidism group had significantly (p=0.001) higher serum neudesin concentrations (4.47 ± 2.28 ng/mL) than in hypothyroidism (1.15 ± 0.43 ng/mL) and control groups (1.06 ± 0.36 ng/mL). A correlation analysis applied to the whole study group revealed a positive correlation between serum neudesin concentration and T4 in patients with hypothyroidism. Conclusions: Due to the relation of increased levels of neudesin in hyperthyroidism, neudesin may be related with one of pathophysiologic pathways of thyroidism. Still, it is not certain that higher neudesin level is involved in the pathogenesis of thyroidism or as a result of the disorder.
Background: Type 2 diabetes mellitus is a condition characterized by an elevation of oxidative stress, which has been implicated in diabetic progression and its vascular complications. Aim: Assessing the impact of gliclazide modified release (MR) versus glimepiride on oxidative stress markers, glycemic indices, lipid profile, and estimated glomerular filtration rate in uncontrolled type 2 diabetic patients on metformin monotherapy. Methods: This was an observational comparative study conducted in Thi-Qar specialized diabetic, endocrine, and metabolism center. Sixty-six patients were randomized into two groups based on the addition of the sulfonylureas (SUs). Group 1 (33 patients) was on gliclazide MR, whereas Group 2 (33 patients)
... Show MoreThe levels of circulating angiogenic and anti-angiogenic factors, namely vascular endothelial growth factor–A (VEGF-A) and soluble vascular endothelial growth factor receptor-1 (sVEGFR-1), have been linked to the development of renal dysfunction due to the proliferation of microvasculature within the kidneys of type 2 diabetic (T2DM) patients. The study aims to scrutinize serum levels of VEGF and sVEGFR-1 in a sample of Iraqi diabetic nephropathy patients to support their reliability as markers for the prediction of nephropathy in type 2 diabetes mellitus patients as well as to assess the ACE inhibitor’s effect on the levels of these two markers. Method: The ninety participants of this case-control study were split into three gr
... Show More